Guest Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  

Current Rheumatology Reviews

Volume 7 Issue 1
ISSN: 1573-3971
eISSN: 1875-6360


   All Titles

  Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective
  pp.77-87 (11) Author: Filip De Keyser

Biologicals revolutionized the treatment of Rheumatoid Arthritis (RA). The targeted suppression of key inflammatory pathways involved in joint inflammation and destruction allows better disease control, which, however, comes at the price of an elevated infection risk due to relative immunosuppression. The disease-related infection risk and the infection risk associated with the use of TNF-α inhibitors (infliximab, adalimumab, etanercept, golimumab and certolizumab pegol), rituximab, abatacept and tocilizumab are discussed. Risk factors clinicians need to take into account when selecting the most appropriate biologic therapy for RA patients, as well as precautions and screening concerning a number of specific infections, such as tuberculosis, intracellular bacterial infections, reactivation of chronic viral infections and HIV are reviewed.

  Keywords: Rheumatoid arthritis, infection, biologicals, targeted therapies, TNF inhibitors, adalimumab, etanercept, golimumab, ertolizumab pegol, rituximab, abatacept, tocilizumab, tuberculosis,, B-cell specific, CD 20 antigen, corticosteroid, comorbidities, disease-modifying antirheumatic drugs (DMARDs), prednisolone, Progressive multifocal leukoencephalopathy, interferon-release assays, tuberculin skin test, tuberculosis-specific interferon-gamma release
  Affiliation: Department of Rheumatology, Ghent University Hospital 0K12, De Pintelaan 185, B-9000 Ghent, Belgium.
  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers


  Copyright © 1994 - 2015   Bentham Science Publishers